The functional genetic variant Arg324Gly of frizzled-related protein is associated with colorectal cancer risk

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1914-1917

  Shanmugam, Kalai S ^a   Brenner, Hermann ^a   Hoffmeister, Michael ^a   Chang Claude, Jenny ^a   Burwinkel, Barbara ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FRIZZLED PROTEIN; GLYCINE; TRYPTOPHAN; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMANY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM CANCER; RISK FACTOR; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ARGININE; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; GLYCINE; GLYCOPROTEINS; HUMANS; LINKAGE (GENETICS); RISK; VARIATION (GENETICS);

EID: 34848913487     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm077     Document Type: Article

References (41)

1. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Lichtenstein,P. et al. (2000) Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
3. Hemminki, K. et al.. (2004) Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol. Biomarkers Prev., 13, 1253-1256.
4. Houlston,R.S. et al. (2004) The search for low-penetrance cancer susceptibility alleles. Oncogene, 23, 6471-6476.
5. de la Chapelle, A. (2004) Genetic predisposition to colorectal cancer. Nat. Rev. Cancer, 4, 769-780.
6. Kinzler,K.W. et al. (1996) Lessons from hereditary colorectal cancer. Cell, 87, 159-170.
7. Bienz,M. et al. (2000) Linking colorectal cancer to Wnt signaling. Cell, 103, 311-320.
8. Wong,N.A. et al. (2002) Beta-catenin - a linchpin in colorectal carcinogenesis? Am. J. Pathol., 160, 389-401.
9. Nelson,W.J. et al. (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303, 1483-1487.
10. Mann,B. et al. (1999) Target genes of beta-catenin-T cell-factor/ lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA, 96, 1603-1608.
11. Reya,T. et al. (2005) Wnt signalling in stem cells and cancer. Nature, 434, 843-850.
12. Kawano,Y. et al. (2003) Secreted antagonists of the Wnt signalling pathway. J. Cell Sci., 116, 2627-2634.
13. Jones,S.E. et al. (2002) Secreted frizzled-related proteins: searching for relationships and patterns. Bioessays, 24, 811-820.
14. Peichel,C.L. et al. (1998) Evaluation of mouse Sfrp3/Frzb1 as a candidate for the 1st, Ul, and Far mutants on chromosome 2. Mamm. Genome, 9, 385-387.
15. Simon,R. et al. (1998) Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol., 185, 345-351.
16. Shiseki,M. et al. (1994) Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res., 54, 5643-5648.
17. Schmitt,J.F. et al. (2002) Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Mol. Endocrinol., 16 213-220.
18. Nishizuka,S. et al. (1998) Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J. Pathol., 185, 38-43.
19. Ransom,D.T. et al. (1998) Loss of heterozygosity on chromosome 2q: possibly a poor prognostic factor in head and neck cancer. Head Neck 20, 404-410.
20. Leyns,L. et al. (1997) Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell, 88, 747-756.
21. Stoehr,R. et al. (2004) Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab. Invest., 84, 465-478.
22. Suzuki,H. et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36, 417-422.
23. Lee,A.Y. et al. (2004) Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23, 6672-6676.
24. Suzuki,H. et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31, 141-149.
25. Klopocki,E. et al. (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int. J. Oncol., 25, 641-649.
26. Ugolini,F. et al. (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most. invasive carcinomas except of the medullary type. Oncogene; 20 5810-5817.
27. Zi,X. et al. (2005) Expression of Frzb/secreted frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res., 65, 9762-9770.
28. Brenner,H. et al. (2006) Does a negative screening colonoscopy ever need to be repeated? Gut, 55, 1145-1150.
29. Frank,B. et al. (2006) ARLTS1 variants and risk of colorectal cancer. Cancer Lett., 244, 172-175.
30. Frank,B. et al. (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev., 15, 2002-2005.
31. Lin,K. et al. (1997) The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. Proc. Natl. Acad. Sci. USA, 94, 11196-11200.
32. Chong,J.M. et al. (2002) Disulfide bond assignments of secreted frizzled-related protein-1 provide insights about frizzled homology and netrin modules. J. Biol. Chem., 277, 5134-5144.
33. Uren,A. et al. (2000) Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem., 275, 4374-4382.
34. Loughlin,J. et al. (2004) Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc. Natl. Acad. Sci. USA, 101, 9757-9762.
35. Frank,B. et al. (2006) Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis, 27, 606-609.
36. Wirtenberger,M. et al. (2006) Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis, 27, 1655-1660.
37. Wirtenberger,M. et al. (2006) Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis, 27, 2201-2208.
38. Derksen,P.W. et al. (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl. Acad. Sci. USA 101, 6122-6127.
39. Gunther,E.J. et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev., 17, 488-501.
40. Kim,J.S. et al. (2002) Proof-of-principle: Oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol. Cancer Ther., 1, 1355-1359.
41. Moon,R.T. et al. (2004) WNT and beta-catenin signalling: Diseases and therapies. Nat. Rev. Genet., 5, 691-701.